Page 7 - Genome Stability News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 
 
 
AstraZeneca and MSD s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers.
 
The three approvals authorise Lynparza for: maintenance treatment after 1st-line chemotherapy containing bevacizumab (genetical recombination) for patients with homologous recombination repair deficient (HRD) ovarian cancer; the treatment of patients with BRCA gene-mutated (BRCAm) castrate-resistant prostate cancer with distant metastasis (mCRPC); and as maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
 
The concurrent approvals by the Japanese Ministry of Health, Labour, and Welfare are based on positive results from the PAOLA-1, PROfound and POLO Phase III trials, which each were published in The New England Journal of Medicine. ....

Dave Fredrickson , Roy Baynes , Adrian Kemp , International Journal Of Clinical Practice , World Health Organization , Company On Twitter Astrazeneca , Research Laboratories , Japanese Ministry Of Health , Investor Relations Team , Head Of Global Clinical Development , Japanese Ministry , New England Journal , Executive Vice President , Oncology Business Unit , Senior Vice President , Global Clinical Development , Chief Medical Officer , World Health , Clinical Oncology , Pancreatic Cancer , Global Trends , World Journal , Ethnic Heterogeneity , Entry Into , Clinical Practice , Genome Stability ,